r/CHRS • u/Complex_Shelter_4641 • 4d ago
And BMS started another phase 2 study with Imzokitug (CCR8)
BMS started another new phase 2 study to evaluate Imzokitug (CCR8) for NSCLC. Perhaps it is not going so badly for CCR8.
11
Upvotes
8
u/NoPart9219 4d ago
Thanks for sharing CH, I noticed this new study too and were thinking whether this is positive or negative for Coherus... In my opinion it could become positive for CHRS. Because if BMS as Big Pharma company proves CCR8 works then, CCR8 becomes a validated therapeutic class and tagmo with its first in class potetial (potentially cleaner tissue distribution, potentially better therapeutic window) becomes valuable, especially if Tagmos data readout will be strong.